Tobramycin%2520eye%2520drop

# Tobramycin Eye Drop ## Overview Tobramycin is an aminoglycoside antibiotic for ophthalmic use, active against many gram-negative and some gram-positive bacteria. Available as 0.3% solution and 0.3% ointment. ## Primary Indications - Bacterial conjunctivitis, blepharitis, keratitis, and other ocular surface infections caused by susceptible organisms - Perioperative prophylaxis (e.g., post-cataract surgery) ## Adult Dosing - **Mild to moderate infection:** 1–2 drops into affected eye(s) every 4 hours - **Severe infection:** 2 drops every hour initially, then taper as clinical improvement occurs - **Ointment:** Apply approximately 1/2-inch strip into conjunctival sac 2–3 times daily; for severe infection, may use every 3–4 hours - Exact frequency and duration depend on local protocol and severity ## Pediatric Dosing - Same concentration (0.3%) as adults; dosing is similar: - **Children:** 1–2 drops every 4 hours; for severe infection, may be given every hour - **Ointment:** 1/2-inch strip 2–3 times daily - **Neonates:** Use with caution due to potential systemic absorption; follow local protocol — dosing typically matches older children but monitor closely ## Dose Adjustments - No dose adjustment needed for ophthalmic use due to negligible systemic absorption - If adjunctive systemic tobramycin is used, adjust based on renal function ## Contraindications - Hypersensitivity to tobramycin, any aminoglycoside, or any component of the formulation - Concurrent use of other topical aminoglycoside drops (additive toxicity risk) ## Adverse Effects - **Common:** ocular burning, stinging, redness, blurred vision, tearing - **Less common:** corneal edema, conjunctival hyperemia, eyelid itching - **Rare:** hypersensitivity reactions (rash, angioedema, anaphylaxis) - **Prolonged use:** risk of superinfection (including fungal) and corneal epithelial toxicity ## Key Drug Interactions - **Minimal systemic interactions** due to low absorption - **Other topical aminoglycosides:** additive toxicity — avoid combination - **Ototoxic/nephrotoxic systemic drugs** (e.g., loop diuretics, other aminoglycosides): theoretical risk if prolonged high-dose ophthalmic use in patients with epithelial defects; monitor as clinically indicated ## Monitoring - Clinical response: reduction in redness, discharge, discomfort within 48–72 hours - Signs of local toxicity: persistent burning, corneal changes - For prolonged therapy (>7–10 days), obtain slit-lamp exam periodically - Serum levels are not required with ophthalmic use alone ## Clinical Pearls - **Shake solution gently** before each use - **Avoid touching** dropper tip to eye, eyelids, or surfaces - Remove contact lenses before administration; do not reinsert during treatment - **Ointment** may cause blurred vision — use at bedtime if daytime regularity is needed - For severe keratitis, **fortified tobramycin** (e.g., 13.6 mg/mL) may be prepared by pharmacy — follow dedicated protocol - Preservative-free formulations are available for patients with multiple daily doses or sensitivity - Not for injection; ophthalmic preparations are not sterile for intravitreal use --- *This information is educational and does not replace professional judgment. Verify current prescribing information, local protocols, and individual patient factors.*